Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XNW28012 |
| Synonyms | |
| Therapy Description |
XNW28012 is an antibody-drug conjugate (ADC) comprising an antibody targeting F3 (TF; tissue factor) linked to a topoisomerase I inhibitor, which potentially induces DNA damage and apoptosis and inhibits tumor cell proliferation (Cancer Res (2026) 86 (7_Supplement): 4437). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XNW28012 | XNW-28012|XNW 28012 | XNW28012 is an antibody-drug conjugate (ADC) comprising an antibody targeting F3 (TF; tissue factor) linked to a topoisomerase I inhibitor, which potentially induces DNA damage and apoptosis and inhibits tumor cell proliferation (Cancer Res (2026) 86 (7_Supplement): 4437). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07707674 | Phase I | XNW28012 | Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer | Not yet recruiting | USA | 0 |